Dainippon Sumitomo's Pan-Asia Trial Problem; Mitsubishi Tanabe Tries To Rebound From Earthquake: Japanese Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Dainippon Sumitomo Pharma Co. Ltd. has a lot riding on anticipated blockbuster Latuda (lurasidone); for the 2011 fiscal year, the company forecasts sales will plunge 4.6% to ¥362 billion due to sales decreases in its major products. Such is the importance of the schizophrenia drug that the company announced during its May 12 full-year earnings call a post-Latuda strategy, even though the schizophrenia drug just launched in the U.S. in February
You may also be interested in...
Success Hinging On Single Platforms For Kissei, Dainippon Sumitomo, NanoCarrier and Eisai: Japan Earnings Roundup (Part 2)
A look at key products that could determine the year ahead for Japanese pharma.
Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2
TOKYO - Astellas provided an update on development for blockbuster-hopeful mirabegron, and the main theme of its progress appears to be safety, or rather waiting for safety data. The company delayed U.S. and EU filings for the drug on regulatory requests for more safety data to assess cardiovascular risk. The company rescheduled mirabegron's FDA filing for 2Q/FY2011, and now everyone is waiting for full results on additional safety studies
Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2
TOKYO - Astellas provided an update on development for blockbuster-hopeful mirabegron, and the main theme of its progress appears to be safety, or rather waiting for safety data. The company delayed U.S. and EU filings for the drug on regulatory requests for more safety data to assess cardiovascular risk. The company rescheduled mirabegron's FDA filing for 2Q/FY2011, and now everyone is waiting for full results on additional safety studies